Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials

CONCLUSION: Consistent with the efficacy of viloxazine ER demonstrated in pivotal trials, viloxazine ER significantly reduced EFDs in subjects with ADHD. Moreover, a substantial proportion of subjects treated with viloxazine ER had large improvements in EFDs, ADHD symptoms, or both.CLINICAL TRIAL REGISTRATION NUMBERS: NCT03247530, NCT03247517, NCT03247543, NCT03247556.PMID:34523063 | DOI:10.1007/s40272-021-00470-2

Source: Paediatric Drugs - September 15, 2021 Category: Pediatrics Authors: Stephen V Faraone Roberto Gomeni Joseph T Hull Gregory D Busse Zare Melyan Jonathan Rubin Azmi Nasser Source Type: research